Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04753216
Status:
COMPLETED
Last Update Posted:
2023-01-19
First Post:
2021-02-10
Brief Title:
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant Recurrent or Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer
Sponsor:
Northwestern University
Organization:
Northwestern University
Organization Data
Organization:
Northwestern University
Class:
OTHER
Study ID:
NU 20G02
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Northwestern University
Lead Sponsor Class:
OTHER
Responsible Party:
Daniela Matei
Responsible Party Title:
Daniela Matei MD
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Northwestern University
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |
| Ipsen Biopharmaceuticals | UNKNOWN |